Cost Effectiveness Analysis of Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Type 2 Diabetes Patients in Iran Publisher Pubmed



Mohammadi A ; Daroudi R ; Mousavi A ; Olyaee Manesh A ; Nasliesfahani E ; Shafiee G ; Heshmat R ; Takian A ; Darvishi A
Source: Expert Review of Pharmacoeconomics and Outcomes Research Published:2025

Abstract

Background: One of the novel methods of blood glucose monitoring is continuous glucose monitoring (CGM). This study aims to evaluate the cost-effectiveness of CGM versus self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes (T2D) in Iran. Methods: A cost-effectiveness analysis with a lifetime horizon was conducted to compare the two monitoring strategies. The patient-level United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model was employed, and clinical and demographic data from Iranian patients enrolled in the Diabetes Care study were extracted for the analysis. Cost-effectiveness was evaluated by calculating incremental cost-effectiveness ratios (ICERs), expressed as cost per QALY gained. Uncertainty in the model was addressed through probabilistic sensitivity analysis using 100 bootstrap iterations. Results: The cost-effectiveness analysis showed that the expected cost of CGM compared to SMBG was $40,444.2. The incremental gain in QALYs was 0.096, resulting in an ICER of $397,644.7 per QALY gained. Based on bootstrap analysis, the 95% CI for the ICER ranged from $271,157.3 to $600,185.2. Conclusion: CGM does not represent a cost-effective alternative to SMBG for patients with T2D in Iran. This finding was supported by bootstrap analysis, which demonstrated a lack of cost-effectiveness across all simulated scenarios. © 2025 Elsevier B.V., All rights reserved.